- Home
- GTEC vs ANEB Comparison
GTEC vs ANEB Comparison
Compare GTEC & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | ANEB |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 96.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTEC | ANEB |
|---|---|---|
| Price | $0.98 | $1.70 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 226.2K | 21.7K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | N/A |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.80 |
| 52 Week High | $2.92 | $3.42 |
Technical Indicators
Market Signals| Indicator | GTEC | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 27.38 |
| Support Level | $1.02 | $1.91 |
| Resistance Level | $1.15 | $2.40 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 7.88 | 12.69 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.